TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31317029
Drug: Dark Chocolate
Normalized name: Ensure Original Dark Chocolate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dark Chocolate (DC) with 7 mg lycopene
Study: 26140823
Drug: Cognitive-Behavioral Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-Behavioral Therapy (CBT) for SAD
Study: 21850574
Drug: Safinamide 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Safinamide 300 mg administered once daily under fasting conditions
Study: 21850574
Drug: Tyramine 200
Normalized name: tyramine
DrugBank: Tyramine (DB08841)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tyramine 200 mg administered alone
Study: 21850574
Drug: Tyramine 50
Normalized name: tyramine
DrugBank: Tyramine (DB08841)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tyramine 50 mg and 100 mg administered on days 5, 6, and 7 respectively
Study: 20015429
Drug: Classical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Classical therapy of thread‐drawing method (control)
Study: 12857474
Drug: Plasma Exchange
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma Exchange (PE) + Continuous Renal Replacement Therapy (CRRT)
Study: 12857474
Drug: Basic Treatment
Normalized name: Basic FGF
DrugBank: Basic Fibroblast Growth Factor (DB14131)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic Treatment
Study: 26935578
Drug: Cilengitide (2000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilengitide (2000 mg IV twice weekly) with metronomic temozolomide (60 mg/m²) and procarbazine (50 or 100 mg)
Study: 22853980
Drug: Docetaxel (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (75 mg/m(2)) plus Ramucirumab (10 mg/kg)
Study: 22853980
Drug: Docetaxel (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (75 mg/m(2)) plus Placebo
Study: 17409312
Drug: Agalsidase beta,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Agalsidase beta, 1 mg/kg biweekly for up to 54 months
Study: 29649631
Drug: Multifactorial behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multifactorial behavioral and medication management intervention delivered via telephone, including up to 36 monthly educational modules, home blood pressure monitoring, and electronic medication management recommendations.
Study: 26516434
Drug: Intramuscular progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intramuscular progesterone (17‐α hydroxyprogesterone caproate)
Study: 24081245
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (prednisone, azathioprine, N-acetylcysteine)
Study: 20851818
Drug: Intracoronary injection
Normalized name: HELIUM 992 mL in 1 L INTRACORONARY GAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary injection of autologous mononuclear bone marrow cells (mBMCs)
Study: 16503543
Drug: Sufentanil intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil intravenous analgesia (1 microg/ml)
Study: 16503543
Drug: Fentanyl intravenous
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl intravenous analgesia (10 microg/ml)
Study: 9480650
Drug: Pefloxacin (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pefloxacin (800 mg daily for 7-10 days)
Study: 9480650
Drug: Routine antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine antibiotics (benzylpenicillin, ampicillin, erythromycin)
Study: 3679106
Drug: Supportive art
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive art therapy group (10 weeks)
Study: 30288918
Drug: Intervention arm
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intervention arm (PSA tests and digital rectal examinations)
Study: 25880054
Drug: 4 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g/day omega‐3 fatty acids plus 400 IU/day vitamin E (OE)
Study: 25880054
Drug: 4 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g/day omega‐3 fatty acids plus vitamin E placebo (OP)
Study: 21497319
Drug: 10-week supervised
Normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 10-week supervised hip flexor stretching program (twice-daily, supervised twice weekly)
Study: 17438512
Drug: Low-dose local
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose local vaginal estrogen therapy
Study: 9825751
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg triple helical collagen type II
Study: 7813220
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg dose of doxycycline
Study: 1209742
Drug: Topical ampicillin
Normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical ampicillin (0.5-1 g into the wound before closure)
Study: 7352522
Drug: Room air
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Room air administration
Study: 28424185
Drug: 3.9 g
Normalized name: aspirin 3.9 GM Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.9 g eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) per day for 6 months
Study: 28424185
Drug: Placebo (4.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (4.2 g oleate per day for 6 months)
Study: 21883635
Drug: Procedural sedation
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procedural sedation with etomidate as the sole agent
Study: 9445321
Drug: Ebselen (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ebselen (150 mg BID for 2 weeks)
Study: 7614505
Drug: cilazapril (CLZ)
Normalized name: cilazapril
DrugBank: Cilazapril (DB01340)
Approvals — FDA: no, EMA: no, PMDA: no
Description: cilazapril (CLZ) 1‐2.5 mg once daily (n = 221)
Study: 7614505
Drug: captopril (CPT)
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: captopril (CPT) 25‐50 mg three times daily (n = 108)
Study: 2515753
Drug: Once‐daily lithium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once‐daily lithium carbonate (Priadal)
Study: 2515753
Drug: Twice‐daily lithium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice‐daily lithium citrate (Litarex)
Study: 983179
Drug: EMB added
Normalized name: EMB
DrugBank: Ethambutol (DB00330)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMB added to chemotherapy regimen
Study: 983179
Drug: EMB and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: EMB and another combination in 54 new cases
Study: 983179
Drug: RMP added
Normalized name: Stahist AD
DrugBank: Chlorcyclizine (DB08936)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: RMP added to treatment in 20 new cases
Study: 29311704
Drug: Kinkeliba (Combretum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kinkeliba (Combretum micranthum) 190 mg × 2/day
Study: 29311704
Drug: Bissap (Hibiscus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bissap (Hibiscus sabdariffa) 320 mg × 2/day
Study: 9850359
Drug: HFA-BDP 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: HFA-BDP 400 micrograms day-1 (delivered as four actuations of 50 micrograms twice daily)
Study: 9850359
Drug: HFA-BDP 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: HFA-BDP 400 micrograms day-1 (delivered as two actuations of 100 micrograms twice daily)
Study: 9850359
Drug: HFA-BDP (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: HFA-BDP (both dosing regimens)
Study: 7866911
Drug: Experimental diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental diet (150 mg calcium and 1600 mg phosphorus daily)
Study: 7866911
Drug: Baseline serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline serum intact parathyroid hormone (PTH) concentration
Study: 2670633
Drug: Erythromycin base
Normalized name: Erythromycin base
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erythromycin base (1 g/day)
Study: 2670633
Drug: Erythromycin ethylsuccinate
Normalized name: Erythromycin Ethylsuccinate
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erythromycin ethylsuccinate (2 g/day)
Study: 773506
Drug: Amitriptyline (75‐225
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (75‐225 mg/day)
Study: 773506
Drug: Flupenthixol (1‐5‐4‐5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flupenthixol (1‐5‐4‐5 mg/day)
Study: 19502645
Drug: Insulin-sensitization therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin-sensitization therapy
Study: 19502645
Drug: Insulin-provision therapy
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin-provision therapy
Study: 22220945
Drug: 1.0 μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 μg/kg DMT
Study: 17378781
Drug: Pre‐emptive stellate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre‐emptive stellate ganglion block (SGB) using 10 ml of ropivacaine
Study: 16323385
Drug: Cognitive rehabilitation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive rehabilitation combined with AChE‐I (rivastigmine) treatment
Study: 12006327
Drug: Alendronate 20
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alendronate 20 mg daily
Study: 12006327
Drug: Ibandronate 5
Normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibandronate 5 mg daily
Study: 10049274
Drug: Abacavir (100,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abacavir (100, 300, 600, 900, and 1,200 mg)
Study: 10049274
Drug: Abacavir (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abacavir (300 mg)
Study: 10049274
Drug: Abacavir (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abacavir (various doses)
Study: 10049274
Drug: Abacavir (caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abacavir (caplet formulation)
Study: 1971645
Drug: Ceftazidime and
Normalized name: Ceftazidime and Avibactam for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime and Gentamicin (C + G)
Study: 1971645
Drug: Ceftazidime, Gentamicin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime, Gentamicin, and Teicoplanin (C + G + T)
Study: 24634622
Drug: Mandibular advancement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mandibular advancement splint (MAS) therapy for 6 months
Study: 21952002
Drug: Exercise Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise Group (EG) - 30 minutes of brisk walking daily for 3 weeks
Study: 17241844
Drug: PSS placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSS placebo gel
Study: 15962898
Drug: ORS/WHO standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: ORS/WHO standard treatment
Study: 15962898
Drug: ORS/plantain solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: ORS/plantain solution (50 g of precooked plantain flour instead of glucose)
Study: 15962898
Drug: ORS/plantain solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: ORS/plantain solution
Study: 9796961
Drug: Cremophor 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cremophor 30 ml/m2
Study: 9796961
Drug: Cremophor 45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cremophor 45 ml/m2 with 35 mg/m2 doxorubicin
Study: 9796961
Drug: Cremophor 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cremophor 60 ml/m2
Study: 9796961
Drug: Cremophor 45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cremophor 45 ml/m2 and 60 ml/m2
Study: 7899064
Drug: Combined concurrent
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined concurrent bronchial artery infusion (BAI) of CDDP (50 mg) and unevenly fractionated radiotherapy
Study: 6150716
Drug: bezafibrate (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: bezafibrate (3 X 200 mg/die)
Study: 6150716
Drug: somatostatin infusion
Normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
Approvals — FDA: no, EMA: no, PMDA: no
Description: somatostatin infusion
Study: 26705681
Drug: Weekly cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly cisplatin (40 mg/m², 7 doses)
Study: 26705681
Drug: Triweekly cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triweekly cisplatin (100 mg/m², 3 doses)
Study: 16614779
Drug: 0.75 ml
Normalized name: ethanol 0.75 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75 ml of 0.3 percent nitroglycerin ointment (2.25 mg nitroglycerin) t.i.d. intra‐anal using the cannula (Group A)
Study: 16614779
Drug: 0.75 ml
Normalized name: ethanol 0.75 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75 ml of 0.3 percent nitroglycerin ointment (2.25 mg nitroglycerin) perianally with the gloved finger (Group B)
Study: 9542752
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid (2 g daily) and d-alpha-tocopherol (1000 IU daily)
Study: 8392820
Drug: Active medication
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active medication (0.3 mg atropine sulfate and 60 mg pseudoephedrine)
Study: 8392820
Drug: Control (inert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (inert capsules)
Study: 3556983
Drug: Intravenous cisapride
Normalized name: Cisapride
DrugBank: Cisapride (DB00604)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous cisapride (8 mg)
Study: 22815422
Drug: Oral ivabradine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ivabradine
Study: 3884469
Drug: Oral metoprolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral metoprolol
Study: 20207878
Drug: Mass azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mass azithromycin distributions (four biannual treatments)
Study: 26286141
Drug: Umeclidinium/vilanterol (UMEC/VI)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Umeclidinium/vilanterol (UMEC/VI) 62.5/25 mcg once daily
Study: 26286141
Drug: Fluticasone propionate/salmeterol
Normalized name: fluticasone propionate/salmeterol 100/50 MCG/INHAL Dry Powder Inhaler, 14 Blisters
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone propionate/salmeterol (FP/SAL) 500/50 mcg twice daily
Study: 23946220
Drug: Low-dose valacyclovir
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose valacyclovir (500 mg twice daily)
Study: 23946220
Drug: High-dose valacyclovir
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose valacyclovir (1 g twice daily)
Study: 21124260
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment for predominant leg pain in DS patients
Study: 21124260
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment for predominant leg pain in SpS patients
Study: 21124260
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment for equal pain groups in DS and SpS patients
Study: 21124260
Drug: Nonoperative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonoperative treatment for predominant LBP patients
Study: 15257469
Drug: 200 micro
Normalized name: Digoxin 200 microgram oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 micro g of budesonide
Study: 15257469
Drug: 800 micro
Normalized name: Fentanyl 800 microgram buccal film
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 micro g of budesonide
Study: 11397610
Drug: Intravenous regional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous regional sympathetic blocks (n = 9)
Study: 9407327
Drug: PUFA-enriched soft
Approvals — FDA: no, EMA: no, PMDA: no
Description: PUFA-enriched soft oil capsules administered after each meal daily for 4 weeks
Study: 9407327
Drug: PUFA-enriched soft
Approvals — FDA: no, EMA: no, PMDA: no
Description: PUFA-enriched soft oil capsules
Study: 8516523
Drug: Fentanyl (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (4 micrograms/kg) and saline (2 ml)
Study: 8516523
Drug: Lidocaine (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (1.5 mg/kg) and fentanyl (4 micrograms/kg)
Study: 31702673
Drug: HT048 (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: HT048 (1000 mg)
Study: 31702673
Drug: HT077 (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: HT077 (400 mg)
Study: 22103814
Drug: Peginterferon/ribavirin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peginterferon/ribavirin therapy
Study: 11887809
Drug: 2-L exchange
Normalized name: Iron(2+) L-ascorbate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-L exchange
Study: 11887809
Drug: 2.5-L exchange
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5-L exchange
Study: 11887809
Drug: 3-L exchange
Normalized name: 3-(L-MENTHOXY)-2-METHYLPROPANE-1,2-DIOL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-L exchange
Study: 11887809
Drug: 2-L exchange
Normalized name: Iron(2+) L-ascorbate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-L exchange (overnight)
Study: 11887809
Drug: 2-L, 2.5-L,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-L, 2.5-L, and 3-L exchanges
Study: 7873457
Drug: formestane (Lentaron)
Normalized name: formestane
DrugBank: Formestane (DB08905)
Approvals — FDA: no, EMA: no, PMDA: no
Description: formestane (Lentaron) 250 mg every 2 weeks by intramuscular injection
Study: 7873457
Drug: tamoxifen 30
Normalized name: tamoxifen 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: tamoxifen 30 mg/day orally
Study: 22204063
Drug: Meloxicam (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meloxicam (0.1 mg/kg i.m.)
Study: 18502208
Drug: 0.625 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625 mg/d of conjugated equine estrogens
Study: 18502208
Drug: Estrogen plus
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen plus progestin (0.625 mg conjugated equine estrogens/d plus 2.5 mg medroxyprogesterone acetate/d)
Study: 16979494
Drug: Experimental antiplaque
Normalized name: cetylpyridinium
DrugBank: Cetylpyridinium (DB11073)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Experimental antiplaque fluoridated formulation
Study: 14609886
Drug: Sibutramine hydrochloride,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sibutramine hydrochloride, 15 mg/d
Study: 11206010
Drug: High-dose continuous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose continuous tamoxifen (200 mg day(-1)), carboplatin (300 mg m(-2) for 3 cycles), and radiotherapy
Study: 11206010
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (tamoxifen, carboplatin, and radiotherapy)
Study: 1445483
Drug: Low-dose oral
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose oral contraceptive (30 micrograms ethinyl estradiol + 150 micrograms desogestrel)
Study: 29377866
Drug: Perineural dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Perineural dexamethasone 0.1 mg/kg (maximum 4 mg) with ropivacaine 0.5% (group D)
Study: 29377866
Drug: Intramuscular dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intramuscular dexamethasone 0.1 mg/kg (maximum 4 mg) with ropivacaine 0.5% (group M)
Study: 29377866
Drug: Ropivacaine 0.5%
Normalized name: ROPivacaine 0.5% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.5% and intramuscular saline (group R)
Study: 26759167
Drug: Cognitive Remediation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Remediation Therapy (CRT) with Treatment as Usual (TAU)
Study: 22007690
Drug: Varenicline 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varenicline 1.0 mg twice daily for 12 weeks with dose titration in the first week
Study: 22007690
Drug: Varenicline 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varenicline 1.0 mg twice daily for 12 weeks
Study: 11464257
Drug: Candesartan cilexetil
Normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Candesartan cilexetil 32 mg once daily
Study: 9681128
Drug: Lenograstim (Granocyte)
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenograstim (Granocyte) therapy
Study: 970597
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg atropine i.v. in normothermia
Study: 970597
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg atropine i.v. in hypothermia
Study: 30642386
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose AmBisome therapy
Study: 26063890
Drug: LET (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: LET (2.5 mg/daily)
Study: 26063890
Drug: LET-CYC (LET
Approvals — FDA: no, EMA: no, PMDA: no
Description: LET-CYC (LET plus oral cyclophosphamide 50mg/daily)
Study: 23583001
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with no planned reminiscence treatment
Study: 21558577
Drug: 6 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg/kg caffeine (6CAF)
Study: 21558577
Drug: 2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/kg caffeine (2CAF)
Study: 2135223
Drug: Telenzepine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telenzepine (5 mg, single oral dose)
Study: 30844672
Drug: Self-affirmation intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-affirmation intervention prior to informing about chemotherapy-related cognitive problems
Study: 30844672
Drug: Information about
Normalized name: Inflammation OTC Bruise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Information about chemotherapy-related cognitive problems
Study: 25816807
Drug: everolimus (trough
Approvals — FDA: no, EMA: no, PMDA: no
Description: everolimus (trough concentration 3‐8 ng/mL or 6‐12 ng/mL) with reduced cyclosporine
Study: 25816807
Drug: everolimus (trough
Approvals — FDA: no, EMA: no, PMDA: no
Description: everolimus (trough concentration 3‐8 ng/mL or 6‐12 ng/mL)
Study: 19392811
Drug: Massed group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Massed group CBT (daily 4‐h sessions in week 1, two 2‐h sessions in week 2 and one 2‐h session in week 3)
Study: 19392811
Drug: Traditional spaced
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional spaced weekly group CBT (13 consecutive, weekly 2‐h sessions)